

NCT ID	NCT06788171
Title	PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Phase	Phase 2
Date Added	2025-03-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT03650348
Title	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Phase	Phase 1
Date Added	2018-08-28
Location	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	PRS-343 in Combination with Atezolizumab, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT01697371
Title	Proton Therapy in the Treatment of Liver Metastases
Phase	Not Applicable
Date Added	2012-10-02
Location	California, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06120127
Title	Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
Phase	Phase 2
Date Added	2023-11-07
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy, PD-1 antibody
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04117087
Title	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Phase	Phase 1
Date Added	2019-10-07
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06300463
Title	Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Phase	Phase 2
Date Added	2024-03-08
Location	New York, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	AGEN1423, Balstilimab, Botensilimab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03868228
Title	PIPAC for the Treatment of Colorectal Peritoneal Metastases
Phase	Phase 1
Date Added	2019-03-11
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT04708470
Title	Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
Phase	Phase 1, Phase 2
Date Added	2021-01-14
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bintrafusp alfa, Entinostat, NHS-IL12
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06149481
Title	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase	Phase 1, Phase 2
Date Added	2023-11-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Recruiting
Drugs	N-803, Retifanlimab, SX-682
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT02484404
Title	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Phase	Phase 1, Phase 2
Date Added	2015-06-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSI-H/ MMRd, MSS/ MMRp